Hormonal
Hypocaloric dieting is the primary driver for improving insulin sensitivity and reducing hyperinsulinaemia in obese women with PCOS, whereas pharmacological interventions (metformin, flutamide) provide no significant additional benefit for these specific metabolic markers.
For obese women with PCOS, prioritizing a caloric deficit (approx. 1200-1400 kcal/day) is the most effective strategy to improve insulin sensitivity. Adding medications like metformin or flutamide does not provide additional metabolic benefits regarding insulin levels compared to diet alone. Medications may still be used for other symptoms (like hirsutism or menstrual regulation), but they should not replace dietary intervention for metabolic health.
Improvement of insulin sensitivity and hyperinsulinaemia appeared to depend on hypocaloric diet, without any further significant effect of the pharmacological treatments, either alone or in combination.
Why this rating
Randomized, single-blind, placebo-controlled trial with clear statistical analysis, though limited by small sample size (n=40).
Source
Effect of flutamide and metformin administered alone or in combination in dieting obese women with polycystic ovary syndrome
Alessandra Gambineri et al. · Clinical Endocrinology · 2004
DOI 10.1111/j.1365-2265.2004.01973.x
More from this paper
- Flutamide, when added to a hypocaloric diet, significantly reduces visceral adipose tissue (VAT), androgen levels (androstenedione, DHEA-S, testosterone), and hirsutism scores in obese women with PCOS, independent of weight loss magnitude.Good
- Metformin, when added to a hypocaloric diet, significantly improves menstrual status (frequency of cycles) in obese women with PCOS, independent of its lack of additional benefit on insulin sensitivity or visceral fat loss compared to diet alone.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →